OMEROS CORPORATION
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $238.1M
- Website
- http://www.omeros.com/
Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT06298955
- Locations
- π¬π§
Omeros Investigational Site, Leeds, United Kingdom
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT06209736
- Locations
- π¬π§
Omeros Investigational Site, Newcastle Upon Tyne, United Kingdom
Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT05972967
- Locations
- π¬π§
Omeros Investigational Site, Leeds, United Kingdom
Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT05889299
- Locations
- πΊπ¦
Omeros Investigational Site, Kyiv, Ukraine
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
Phase 2
Recruiting
- Conditions
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT05855083
- Locations
- πͺπΈ
Omeros Investigational Site, Pamplona, Spain
Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Omeros Corporation
- Registration Number
- NCT04247906
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 356
- Registration Number
- NCT03608033
- Locations
- π¬π§
Omeros Investigational Site, London, United Kingdom
πΊπΈOmeros Investigation Sites, Phoenix, Arizona, United States
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 80
- Registration Number
- NCT03205995
- Locations
- πΊπΈ
Omeros Investigational Site, Chicago, Illinois, United States
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT02682407
- Locations
- ππ°
Omeros Investigational Site, Sha Tin, Hong Kong
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 58
- Registration Number
- NCT02222545
- Locations
- πΉπ
Omeros Investigational Site, Pathum Thani, Thailand
Β© Copyright 2024. All Rights Reserved by MedPath